Corcept (CORT) Gets FDA Approval for Korlym

Corcept Therapeutics Incorporated (Nasdaq: CORT) reports that the U.S. Food and Drug Administration (FDA) has approved Korlym" (mifepristone 300 mg tablets) as a once-daily oral medicine to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have diabetes mellitus type 2 or glucose intolerance and have failed surgery or are not candidates for surgery.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Japan approves BioCryst's Orladeyo for children ages 2 to 12 with HAE
• OneMeta launches on-premises AI translation tool for secure environments
• Rescale adds CoreWeave cloud support for AI and simulation workloads